Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People Briefs: New CEO At Hologic; Departures At MDMA

This article was originally published in The Gray Sheet

Executive Summary

Hologic appoints former Stryker CEO MacMillan president and CEO. Two staffers leave MDMA for device firms. More people briefs.

You may also be interested in...



News We’re Watching: Two Join Illumina Board, FDA Plans Health Equity Meeting, Pre-Eclampsia Test Cleared

This week, Illumina’s board added two independent members; the VA and the FDA agreed to collaborate on supply chain issues; and Think Surgical, Thermo Fisher Scientific and Blue Earth all landed FDA clearances.

Two Device Industry Veterans Join Boston Scientific’s Board

Hologic CEO Stephen MacMillan and former Covidien exec Charles Dockendorff have been elected to Boston Scientific’s board of directors, adding significant device industry expertise to the mix. MacMillan will be the only active device industry CEO for another company on the board.

People Briefs: Varian Medical Systems, MDMA, Precedent Spine Health

Varian Medical Systems names R. Andrew Eckert Chairman of the Board. Medical Device Manufacturers Association taps new VP of government affairs. Precedent Spine Health Appoints CEO. More people briefs.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032677

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel